Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

The company pointed to "recent market challenges" and "share price decline" as reasons for Lars Fruergaard Jørgensen's ...

Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...